通心络联合规范西医治疗对缺血性心肌病患者心肌纤维化的影响  

Effect of combininf Tongxinluo with standard modern medicine treatment on myocardial fibrosis in patients with ischemic cardiomyopathy

作　　者：李少霞[1] 李劲草[1] 张鹏[1] 黄冰生[1] 解强[1] 程颖[1] 

机构地区：[1]南方医科大学附属何贤纪念医院心内科,广州511400

出　　处：《新医学》2013年第10期681-684,共4页Journal of New Medicine

基　　金：广东省中医药管理局资助项目(20121012)

摘　　要：目的探讨通心络联合规范西医治疗对缺血性心肌病(ICM)患者心肌纤维化(MF)的影响。方法将83例ICM患者随机分为2组,对照组(n=41)及通心络治疗组(n=42)。对照组采用规范的西医治疗;通心络治疗组在规范的西医治疗基础上,加用通心络治疗(每次3粒,3次/日)。随访半年,所有研究对象在初始及随访结束时两次行血清hsCRP、Ⅰ型前胶原羧基末端前肽(PIP)、血清Ⅰ型胶原羧基端交联肽(CITP)及Ⅲ型N端胶原前肽(PIIINP)水平检测。结果研究结束时,与对照组比较,通心络治疗组血清hsCRP、PIP/CITP比值及PIIINP水平明显降低,血清CITP水平明显升高,差异有统计学意义(P<0.05);血清hsCRP与PIP/CITP比值存在正相关。结论通心络可降低ICM患者MF水平。Objective To investigate the effect of combined application of Tongxinluo and standard modern medicine treatment on myocardial fibrosis （ MF ） in patients with ischemie cardiomyopathy （ICM）. Methods Eighty three patients with ICM were randomly divided into two groups： control group （n = 41 ） and Tongxinluo treatment group （ n = 42）. Control group was treated with standard Western medical treatment; and Tongxinluo treatment group was given Tongxinluo （3, rid ） in addition to western medicineAfter 6 months＇ treatment, levels of serum hsCRP, carboxyl-terminal propeptide of procollagen type I （PIP） , carboxyl- termi- nal telopeptide of collagen type I （CITP） and amino-terminal propeptide of procollagen type III （PIIINP） were observed. Results At the end of this study, Tongxinluo treatment group manifested withsignificantly de- creased levels of serum hsCRP, PIP/CITP and PIIINP, and increased levels of serum CITP in comparison with control group （ P 〈 0.05 ）. There was positive correlation between hsCRP and PIP/CITP. Conclusion Tongx- inlong might improve MF in patients with ICM.

关 键 词：通心络 缺血性心肌病 心肌纤维化 C反应蛋白 

分 类 号：R542.2[医药卫生—心血管疾病]